Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 4
1987 7
1988 11
1989 17
1990 44
1991 67
1992 71
1993 100
1994 105
1995 131
1996 157
1997 134
1998 152
1999 154
2000 175
2001 237
2002 237
2003 236
2004 255
2005 303
2006 268
2007 226
2008 261
2009 190
2010 208
2011 194
2012 180
2013 178
2014 178
2015 150
2016 174
2017 134
2018 126
2019 107
2020 120
2021 107
2022 92
2023 8
Text availability
Article attribute
Article type
Publication date

Search Results

5,099 results
Results by year
Filters applied: . Clear all
Page 1
Statin therapy increases lipoprotein(a) levels.
Tsimikas S, Gordts PLSM, Nora C, Yeang C, Witztum JL. Tsimikas S, et al. Eur Heart J. 2020 Jun 21;41(24):2275-2284. doi: 10.1093/eurheartj/ehz310. Eur Heart J. 2020. PMID: 31111151
-statin trials, with pre- and on-treatment (4-104 weeks) Lp(a) levels. Statins included atorvastatin 10 mg/day and 80 mg/day, pravastatin 40 mg/day, rosuvastatin 40 mg/day, and pitavastatin 2 mg/day. ...-statin pooled analysis, the ratio of geometric means (95% CI) for ato …
-statin trials, with pre- and on-treatment (4-104 weeks) Lp(a) levels. Statins included atorvastatin 10 mg/day and 80 mg/day, pravastatin
Pravastatin for Preventing and Treating Preeclampsia: A Systematic Review.
Esteve-Valverde E, Ferrer-Oliveras R, Gil-Aliberas N, Baraldès-Farré A, Llurba E, Alijotas-Reig J. Esteve-Valverde E, et al. Obstet Gynecol Surv. 2018 Jan;73(1):40-55. doi: 10.1097/OGX.0000000000000522. Obstet Gynecol Surv. 2018. PMID: 29368790 Review.
IMPORTANCE: We have performed a systematic search to summarize the role of statins for preventing and treating severe preeclampsia. OBJECTIVE: The aim of this study was to examine whether pravastatin is a useful and safe alternative for treating preeclampsia during pregnan …
IMPORTANCE: We have performed a systematic search to summarize the role of statins for preventing and treating severe preeclampsia. OBJECTIV …
A randomized pilot clinical trial of pravastatin versus placebo in pregnant patients at high risk of preeclampsia.
Costantine MM, West H, Wisner KL, Caritis S, Clark S, Venkataramanan R, Stika CS, Rytting E, Wang X, Ahmed MS; Eunice Kennedy Shriver National Institute of Child Health and Human Development Obstetric-Fetal Pharmacology Research Centers (OPRC) Network, Bethesda, MD. Costantine MM, et al. Am J Obstet Gynecol. 2021 Dec;225(6):666.e1-666.e15. doi: 10.1016/j.ajog.2021.05.018. Epub 2021 May 24. Am J Obstet Gynecol. 2021. PMID: 34033812 Free PMC article. Clinical Trial.
Here, we report a follow-up, randomized trial of 20 mg pravastatin versus placebo among pregnant women with previous preeclampsia who required delivery before 34+6 weeks' gestation with the objective of evaluating the safety and pharmacokinetic parameters of pravastatin
Here, we report a follow-up, randomized trial of 20 mg pravastatin versus placebo among pregnant women with previous preeclampsia who …
Pravastatin sodium.
Al-Badr AA, Mostafa GA. Al-Badr AA, et al. Profiles Drug Subst Excip Relat Methodol. 2014;39:433-513. doi: 10.1016/B978-0-12-800173-8.00008-8. Profiles Drug Subst Excip Relat Methodol. 2014. PMID: 24794911 Review.
Pravastatin sodium is an [HMG-CoA] reductase inhibitor and is a lipid-regulating drug. ...The chapter also contains the pharmacokinetics, metabolism, stability, and articles that reviewed pravastatin sodium manufacturing, characterization, and analysis. One hundred
Pravastatin sodium is an [HMG-CoA] reductase inhibitor and is a lipid-regulating drug. ...The chapter also contains the pharmacokinet
Pravastatin: an evidence-based statin?
del Sol AI, Nanayakkara PW. del Sol AI, et al. Expert Opin Drug Metab Toxicol. 2008 Jun;4(6):821-5. doi: 10.1517/17425255.4.6.821. Expert Opin Drug Metab Toxicol. 2008. PMID: 18611121 Review.
With 40 mg pravastatin daily, total cholesterol can be reduced by 25-34% with a very consistent risk reduction of 24% of death from cardiovascular diseases. ...Therefore, when the expected 25-34% LDL cholesterol lowering would be enough to reach an LDL<2.5 mmol/l, treat …
With 40 mg pravastatin daily, total cholesterol can be reduced by 25-34% with a very consistent risk reduction of 24% of death from c …
Pravastatin to treat and prevent preeclampsia. Preclinical and clinical studies.
Girardi G. Girardi G. J Reprod Immunol. 2017 Nov;124:15-20. doi: 10.1016/j.jri.2017.09.009. Epub 2017 Sep 29. J Reprod Immunol. 2017. PMID: 29028516 Review.
In addition, pravastatin is hydrophilic and has a limited passage through the placenta, diminishing any safety concerns. Several pilot studies suggest that pravastatin may be a good option to prevent and treat preeclampsia in women. ...
In addition, pravastatin is hydrophilic and has a limited passage through the placenta, diminishing any safety concerns. Several pilo …
Pharmacogenomic importance of pravastatin.
Peters B, Maitland-van der Zee AH. Peters B, et al. Pharmacogenomics. 2008 Sep;9(9):1207-10. doi: 10.2217/14622416.9.9.1207. Pharmacogenomics. 2008. PMID: 18781848 Review.
In developed countries, cardiovascular disease is one of the leading causes of death. Among other statins, pravastatin is abundantly prescribed to reduce risk of coronary artery disease by lowering cholesterol. Genetic factors are thought to be partly responsible for the i …
In developed countries, cardiovascular disease is one of the leading causes of death. Among other statins, pravastatin is abundantly …
Pravastatin: a review of its use in elderly patients.
Bang LM, Goa KL. Bang LM, et al. Drugs Aging. 2003;20(14):1061-82. doi: 10.2165/00002512-200320140-00005. Drugs Aging. 2003. PMID: 14651445 Review.
Coadministration of cholestyramine, another lipid-lowering agent, further enhanced the lipid-lowering effects of pravastatin in elderly patients. Data from the large, long-term (3-6 years) PROspective Study Of Pravastatin in the Elderly at Risk (PROSPER), Cholestero …
Coadministration of cholestyramine, another lipid-lowering agent, further enhanced the lipid-lowering effects of pravastatin in elder …
[Research and development of pravastatin].
Kishida Y, Naito A, Iwado S, Terahara A, Tsujita Y. Kishida Y, et al. Yakugaku Zasshi. 1991 Sep;111(9):469-87. doi: 10.1248/yakushi1947.111.9_469. Yakugaku Zasshi. 1991. PMID: 1762049 Review. Japanese.
The first potent inhibitor, ML-236B (compactin), was found from the culture broth of Penicillium citrinum. Among many derivatives of ML-236B, pravastatin sodium (hereafter refer to pravastatin) was finally selected because of its potency and tissue selectivity. Sinc …
The first potent inhibitor, ML-236B (compactin), was found from the culture broth of Penicillium citrinum. Among many derivatives of ML-236B …
5,099 results